Anebulo Pharmaceuticals (ANEB) Net Income (2020 - 2025)
Anebulo Pharmaceuticals (ANEB) posted quarterly Net Income of -$2.6 million for Q4 2025, up 4.82% year-over-year from -$2.4 million in Q4 2024, and up 29.62% quarter-over-quarter from -$3.6 million in Q3 2025.
Anebulo Pharmaceuticals (ANEB) Net Income (2020 - 2025) Analysis & Trends
Anebulo Pharmaceuticals (ANEB) has reported Net Income for 6 consecutive years, with -$2.6 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Net Income rose 4.82% year-over-year to -$2.6 million; the TTM figure through Dec 2025 stood at -$10.5 million (down 22.81% YoY), while the FY2025 annual figure was -$9.4 million, down 13.39% from the prior year.
- Net Income rose to -$2.6 million in Q4 2025 per ANEB's latest filing, from -$3.6 million in the prior quarter.
- Across five years, Net Income topped out at -$555832.0 in Q1 2021 and bottomed at -$7.2 million in Q2 2023.
- Historically, Net Income has averaged -$3.0 million across 5 years, with a median of -$2.8 million in 2023.
- Annual changes were most pronounced in 2021 — Net Income tumbled 955.55% — and 2024, when it surged 80.52%.
- Anebulo Pharmaceuticals' Net Income stood at -$3.5 million in 2021, then retreated by 13.64% to -$3.9 million in 2022, then increased by 28.4% to -$2.8 million in 2023, then increased by 5.0% to -$2.7 million in 2024, then rose by 4.82% to -$2.6 million in 2025.
- Business Quant data shows ANEB's Net Income at -$2.6 million in Q4 2025, -$3.6 million in Q3 2025, and -$2.2 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.79 Bn | 131.94 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 86.74 Bn | 78.74 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 65.48 Bn | 60.29 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 59.32 Bn | 54.18 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 42.08 Bn | 36.98 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.81 Bn | 28.50 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -355.03 Mn |
| 8 | Insmed | 27.56 Bn | 26.40 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.29 Bn | 26.45 Bn | - | 81.49 Mn |
| 10 | Anebulo Pharmaceuticals | 16.43 Mn | 16.43 Mn | - | -2.55 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -2.55 Mn |
| Sep 30, 2025 | -3.63 Mn |
| Jun 30, 2025 | -2.24 Mn |
| Mar 31, 2025 | -2.04 Mn |
| Dec 31, 2024 | -2.68 Mn |
| Sep 30, 2024 | -2.49 Mn |
| Jun 30, 2024 | -1.40 Mn |
| Mar 31, 2024 | -1.95 Mn |
| Dec 31, 2023 | -2.82 Mn |
| Sep 30, 2023 | -3.05 Mn |
| Jun 30, 2023 | -7.18 Mn |
| Mar 31, 2023 | -3.20 Mn |
| Dec 31, 2022 | -3.94 Mn |
| Sep 30, 2022 | -2.97 Mn |
| Jun 30, 2022 | -4.55 Mn |
| Mar 31, 2022 | -5.65 Mn |
| Dec 31, 2021 | -3.47 Mn |
| Sep 30, 2021 | -1.55 Mn |
| Jun 30, 2021 | -2.47 Mn |
| Mar 31, 2021 | -555,832.00 |